the firm's post-grant practitioners are some of the most experienced in the country.

Technologies

Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our

History

Get to know our History

1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our

ACCOLADES

A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.

OPPORTUNITIES FOR YOUR

Career

OPPORTUNITIES FOR YOUR Career

From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +


Tokyo Office

Telephone: +81-3-6212-0550
Learn More +

Downloadable

Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

Stay informed with

Our Blogs

Hedge Your Bets in TC 1600 PGRs

  • November 30, 2018
  • Article

Associated Practices

Associated Technologies


      Post grant reviews (PGRs) have proven to be more popular in the biotechnology space (TC 1600) than any other art unit, with 42—or 28.1%—of the PGRs filed to date classified as TC 1600 patents.[1]  By way of comparison, TC 1600 makes up just 10.1% of all IPRs filed to date.  Perhaps not surprisingly, PGRs are appealing for challengers of biotechnology patents because written description, enablement, and indefiniteness can all be raised, and these § 112 hurdles tend to be more challenging in the unpredictable arts of TC 1600. 

      Challengers generally attempt to maximize their chances by alleging grounds based on both prior art and § 112.  Indeed, 73% of TC 1600 PGRs include both types of grounds, while 14.6% raise only prior art, and 12.2% include only § 112 grounds.

      The importance of hedging your bet by including multiple types of challenges is illustrated in the final written decision in PGR2017-00022, where the Board found that Grünenthal’s petition rendered all claims in Antecip’s U.S. Patent No. 9,408,862 unpatentable.

      The ’862 patent, covering oral pharmaceutical compositions containing zoledronic acid, was challenged in multiple ways, with each claim attacked by at least one prior art ground as well as one § 112 ground.  And, this approach proved essential.  Several pages of the final written decision are dedicated to determining whether one of Grünenthal’s references—a conference poster—qualified as prior art.  Grünenthal argued that the poster was publicly presented and available to the public well before the priority date, but Antecip argued that Grünenthal had not provided sufficient evidence to show that it qualified as prior art. 

      The Board ultimately agreed, holding that Grünenthal’s corroborating evidence was untimely as it was included in the Reply rather than in the Petition. But even if this evidence was considered, the Board held that Grünenthal “has not met its burden of establishing that the [poster] qualifies as prior art.”  Specifically, the Board held that Grünenthal presented “no meaningful evidence or related discussion suggesting that the [poster] was displayed in a manner that would have allowed interested and ordinarily skilled artisans exercising reasonable diligence to locate the poster.”  Thus, this reference was not considered in the two grounds it was used. 

      Because this reference was not used, a handful of claims were only held unpatentable on lack of enablement grounds, leaving open the possibility to save some claims on appeal—particularly because one judge dissented from the enablement finding. 

      This decision provides a clear lesson from the PTAB:  all evidence necessary to prove that key art relied upon actually qualifies as prior art must be presented in a petition.  Luckily for Grünenthal, they had a back-up enablement argument that saved the day.

 

 

 

[1] For an up-to-date listing of all PGRs and IPRs filed in TC1600, visit Oblon’s TC 1600 Post Grant Library, available at https://www.oblon.com/ptab-proceedings/tc-1600-post-grant-library/.